Abeona Therapeutics ABEOW 深 沪
已收盘 01-09 16:00:00 美东时间
0.0698
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0698
- 总市值 2.11亿
- 52周最高 4.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.021
- 委 比 0.00%
- 总股本 30.28亿
- 历史最高 17.56
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.021
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics Inc. granted restricted stock equity awards to two new non-executive employees, totaling up to 7,200 shares. The shares vest annually over three years, contingent on continued employment. Abeona is a biopharmaceutical company developing cell and gene therapies, including ZEVASKYN® for recessive dystrophic epidermolysis bullosa and ABO-701 for solid tumors.
10-02 11:30
Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Deutsche Bank cut the price target for Xenon Pharmaceuticals Inc (NASDAQ:XENE) from $90 to $46. Deutsche Bank ...
09-18 20:31
Roth Capital Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $17
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Abeona Therapeutics (NASDAQ:ABEO) with a Buy rating and announces Price Target of $17.
09-17 18:09
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
Abeona Therapeutics has activated the University of Florida Health (UF Health) as the eighth Qualified Treatment Center (QTC) for administering ZEVASKYN, the first and only autologous gene-modified cellular sheets for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). This expansion aims to increase access to the innovative gene therapy for patients in Florida and the southeastern United States. ZEVASKYN addresses...
09-16 11:30
Abeona Therapeutics Updates Investor Presentation at Conference
Abeona Therapeutics ( ($ABEO) ) has shared an update. Abeona Therapeutics Inc. ...
09-16 00:47
Oppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21
Oppenheimer analyst Jeff Jones maintains Abeona Therapeutics (NASDAQ:ABEO) with a Outperform and lowers the price target from $22 to $21.
08-15 01:00
Abeona Therapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results.
Abeona Therapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results.
08-13 19:59
Abeona Therapeutics Activates Cincinnati Children’s As Seventh Qualified Treatment Center For Administration Of ZEVASKYN To Treat Wounds In Patients With Recessive Dystrophic Epidermolysis Bullosa
Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the activation of Cincinnati Children’s as the seventh Qualified Treatment Center (QTC) for the administration of ZEVASKYN® (prademagene zami...
07-21 19:37
Abeona Therapeutics announces resignation of board member
Abeona Therapeutics ( ($ABEO) ) just unveiled an update. On June 11, 2026, Abeo...
06-12 20:01
